Join to View Full Profile
460 W 12th AveColumbus, OH 43210
Phone+1 614-366-0172
Dr. Li is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a cancer immunologist and medical oncologist with passion in discovering and translating knowledge to improve care of patients with cancer.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1997 - 1999
Montefiore Medical CenterResidency, 1994 - 1997
Henan Medicine UniversityClass of 1984
Certifications & Licensure
OH State Medical License 2019 - 2026
SC State Medical License 2010 - 2019
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected member of ASCI, AAP and AAAS
Publications & Presentations
PubMed
- A novel TLR4 accessory molecule drives hepatic oncogenesis through tumor-associated macrophages.Doyeon Kim, Carter A Allen, Dongjun Chung, Lingbin Meng, Xiaoli Zhang
Cancer Letters. 2025-04-01 - HuR inhibition reduces post-ischemic cardiac remodeling by dampening myocyte-dependent inflammatory gene expression and the innate immune response.Samuel Slone, Sarah R Anthony, Lisa C Green, Sharon Parkins, Pooja Acharya
FASEB Journal. 2025-03-31 - Recent advances in therapeutic strategies for non-small cell lung cancer.Po-Lan Su, Naoki Furuya, Alahmadi Asrar, Christian Rolfo, Zihai Li
Journal of Hematology & Oncology. 2025-03-27
Press Mentions
Research Area of Concentration: Dr. Peter Mohler Shares UpdateAugust 10th, 2023
Grant Support
- Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung CancerOHIO STATE UNIVERSITY2024–2029
- Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial MetabolismOHIO STATE UNIVERSITY2021–2026
- Targeting GRP94-TGF-beta Pathway for Cancer ImmunotherapyOHIO STATE UNIVERSITY2021–2026
- Targeting GRP94-TGF-beta Pathway for Cancer ImmunotherapyOHIO STATE UNIVERSITY2021–2026
- Overcoming hypoxic resistance to anti-cancer therapyOHIO STATE UNIVERSITY2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
